Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca    AZN   GB0009895292

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Falls in Burberry, housebuilders pile pressure on FTSE

share with twitter share with LinkedIn share with facebook
share via e-mail
11/09/2017 | 06:07pm CET
The London Stock Exchange is seen attached to the building London

LONDON (Reuters) - Heavy losses from luxury group Burberry weighed on Britain's top share index on Thursday which hit a two-week low as investors showed anxiety about the retail and housebuilding sectors.

The FTSE 100 <.FTSE> index sank 0.6 percent, slightly outperforming a sharp slump in European stocks, while mid-caps <.FTMC> dropped 1.1 percent.

Burberry (>> Burberry Group) fell 9.4 percent, its biggest one-day loss since September 2012, on the high cost of its plans to move upmarket by focusing on leather goods and fashion and cutting sales to non-luxury stores.

"Today's results were overshadowed by the strategic reset [...] which implies no sales and earnings growth in 2019 and 2020," said Berenberg luxury analysts.

"Despite the short-term downside risk to Burberry's earnings, today's strategy update left us feeling confident about the CEO's vision," they added.

Burberry's shares had gained 34 percent so far this year, outstripping the FTSE 100 which has gained just over 5 percent.

In a weak day for retailers, Sainsbury's (>> J Sainsbury) shares fell 1.8 percent after lower sales confirmed investors' fears about inflationary pressures on consumers.

"A 2 percent first-half profit beat and confirmed full-year guidance does little to change our concerns around Sainsbury's vulnerability to a weakening UK consumer outlook," said Jefferies analysts.

Marks & Spencer (>> Marks & Spencer Group) also fell 2.4 percent, while small-cap department store Debenhams (>> Debenhams Plc) sank 6.9 percent.

Housebuilders also suffered, with shares in Persimmon (>> Persimmon), Taylor Wimpey (>> Taylor Wimpey) and Barratt Developments (>> Barratt Developments) falling by 2.8 percent to 3.9 percent after a survey showed house prices in Britain were no longer rising.

Weak results added to price pressures for mid-cap builder Redrow (>> Redrow plc), which was down 6.6 percent . Bovis Homes (>> Bovis Homes Group), Crest Nicholson (>> Crest Nicholson Holdings PLC) and Bellway (>> Bellway) fell 4.9 to 5.7 percent.

"Redrow's announcement will do little to cool any jitters around market sentiment on new housing," said analysts at Davy Research.

Business media company Informa (>> Informa PLC) was the top gainer, up 4.3 percent. The company reported revenue rose in the first 10 months of 2017, buoyed by its global exhibitions business.

Outside the blue chips, a trading update weighed on Hikma (>> Hikma Pharmaceuticals), which dropped 5.5 percent after cutting its generic sales forecast again. Its partner Vectura Group (>> Vectura Group PLC) fell 7.7 percent.

Both companies are in a dispute with the U.S. Food and Drug Administration over plans to launch a generic copy of GlaxoSmithKline's (>> GlaxoSmithKline) lung drug Advair in the U.S. market.

Inmarsat (>> Inmarsat) sank 9 percent after the satellite firm narrowed its guidance for full-year earnings.

(Reporting by Kit Rees, editing by Larry King and Alexander Smith)

By Kit Rees and Helen Reid

Valeurs citées dans l'article
ChangeLast1st jan.
BARRATT DEVELOPMENTS 1.03% 568 Delayed Quote.-15.24%
BELLWAY 0.70% 3150 Delayed Quote.-14.01%
BOVIS HOMES GROUP 0.51% 1084.5 Delayed Quote.-8.40%
BURBERRY GROUP 0.42% 1567 Delayed Quote.-13.23%
CREST NICHOLSON HOLDINGS PLC -0.28% 490 Delayed Quote.-12.44%
DEBENHAMS PLC 0.35% 28.7 Delayed Quote.-17.76%
FTSE 100 INDEX 0.28% 7234.11 End-of-day quote.-5.90%
GLAXOSMITHKLINE 0.10% 1326.32 Delayed Quote.-1.67%
HIKMA PHARMACEUTICALS -3.29% 953.2 Delayed Quote.-20.55%
INFORMA PLC 0.99% 693.2 Delayed Quote.-6.26%
INMARSAT -4.18% 458.7 Delayed Quote.-12.08%
J SAINSBURY 0.28% 255.2 Delayed Quote.2.69%
MARKS & SPENCER GROUP -0.57% 298.7 Delayed Quote.-6.93%
PERSIMMON 0.93% 2488 Delayed Quote.-11.43%
REDROW PLC -0.83% 599 Delayed Quote.-11.38%
TAYLOR WIMPEY 0.21% 191.45 Delayed Quote.-9.52%
VECTURA GROUP PLC -3.74% 74.55 Delayed Quote.-33.98%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ASTRAZENECA
02/20MERCK AND : Groundbreaking lung cancer approval a big boost for AZs Imfinzi
02/19ASTRAZENECA : European indices gain tracking Asian equities
02/19MERCK AND : - Selumetinib Granted Orphan Drug Designation by the U.S. FDA for Ne..
02/19ASTRAZENECA : FDA grants EAP designation to Guardant's NGS-based liquid biopsy
02/19ASTRAZENECA : US FDA approves Imfinzi for unresectable Stage III non-small cell ..
02/19AstraZeneca's immunotherapy drug wins key lung cancer approval
02/19ASTRAZENECA : Cell Lung Cancer Treatment Imfinzi Gets FDA Approval
02/19ASTRAZENECA : IMFINZI approved for Stage III nsclc
02/18ASTRAZENECA : lung cancer drug gets OK from FDA
02/17ASTRAZENECA : US FDA approves Imfinzi for unresectable Stage III non-small cell ..
More news
News from SeekingAlpha
02/20Ionis out-licenses kidney disease candidate to AstraZeneca for up to $330M 
02/19AstraZeneca Scores FDA First, Time To Capitalize Before Competitors Roll In 
02/18BioSci Rounds Report For Feb. 16, 2018 
02/17FDA OKs expanded use for AstraZeneca's Imfinzi 
02/16Celgene's Otezla-Colitis Story; Implications For Other Biotechs 
Financials ($)
Sales 2018 22 326 M
EBIT 2018 5 645 M
Net income 2018 2 145 M
Debt 2018 14 000 M
Yield 2018 4,16%
P/E ratio 2018 33,05
P/E ratio 2019 26,18
EV / Sales 2018 4,38x
EV / Sales 2019 4,12x
Capitalization 83 737 M
Duration : Period :
AstraZeneca Technical Analysis Chart | AZN | GB0009895292 | 4-Traders
Technical analysis trends ASTRAZENECA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 33
Average target price 72,8 $
Spread / Average Target 10%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Dunoyer Chief Financial Officer & Executive Director
Sean Bohen Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA-7.96%83 737
JOHNSON & JOHNSON-7.19%357 710
NOVARTIS-3.37%226 667
PFIZER-2.84%216 135
ROCHE HOLDING LTD.-9.37%207 826
MERCK AND COMPANY-0.50%153 359